No Differences in Outcomes Between JAK2 V617F-Positive Patients With Variant Allele Fraction < 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis

JAK2 V617F mutation is one of the major criteria in the diagnosis of myeloproliferative neoplasms (MPN) and its variant allele fraction (VAF) determines the disease phenotype and outcomes. This study aimed to define characteristics and outcomes of patients with JAK2 V617F VAF < 2% compared to patients with VAF 2%-10%.